Jefferies Raises Price Target on EZCORP (EZPW) to $6 Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Unusual 11 Mid-Day Movers 5/10: (CCXI) (CROX) (SODA) Higher; (EPRS) (NLNK) (JGW) Lower
May 10, 2016 12:50 PM EDTEPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) 55.1% LOWER; announced reprioritization of the companys pipeline to focus exclusively on developing biosimilars for the treatment of rare diseases. This includes reallocating the Companys resources to focus on the development of BOW080 (eculizumab; reference biologic Soliris®) for the potential treatment of ultra-rare blood disorders and BOW070 (tocilizumab; reference biologic Actemra) for the potential treatment of an uncommon lymphoproliferative disorder known as Castlemans disease.
ChemoCentryx, Inc. (Nasdaq: CCXI) 41.0% HIGHER; Vifor Pharmaand and... More
